Skeletal Manifestations, Bone Pain, and BMD Changes in Albanian Type 1 Gaucher Patients Treated with Taliglucerase Alfa

Table 1

General data of our patients.

Number of patients at baseline	24
Number of patients at the end of study	20
Gender (F-M)	7/13 (end of the study)
Genotype	19/p.Asn409Ser:p.His294Gln/pAsp448His
	2/p.Asn409Ser:pArg 502His
	1/p.Asn409Ser:pSer146Leu
	1/p.Asn409Ser:p/Arg86
	1/p. Asn409Ser: p/LeuProfs4: Arg87Trp
Age at baseline	28.7 ± 16.5 (min age: 7 y, max age: 72 y)
Children (under 18 y)/adults	8/16
Naïve patients	8 patients
Switched patients	12 patients switched at baseline (imiglucerase to taliglucerase)
	2 patients switched during FU (taliglucerase to velaglucerase)
Splenectomized	2